113 related articles for article (PubMed ID: 18587567)
21. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
23. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
24. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
[TBL] [Abstract][Full Text] [Related]
25. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
26. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
27. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
28. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
29. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
31. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
32. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
[TBL] [Abstract][Full Text] [Related]
33. Sex differences in CYP3A activity using intravenous and oral midazolam.
Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
[TBL] [Abstract][Full Text] [Related]
34. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
35. Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats.
Kurosawa S; Uchida S; Ito Y; Yamada S
Xenobiotica; 2009 Feb; 39(2):162-70. PubMed ID: 19255942
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Uehara S; Inoue T; Utoh M; Toda A; Shimizu M; Uno Y; Sasaki E; Yamazaki H
Xenobiotica; 2016; 46(2):163-8. PubMed ID: 26114209
[TBL] [Abstract][Full Text] [Related]
37. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
38. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
39. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
[TBL] [Abstract][Full Text] [Related]
40. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]